Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

• VLD rivaroxaban significantly reduces platelet dependent thrombin generation and thrombusformation on top of DAPT in patients with ACS.
• Adjunctive treatment with VLD rivaroxaban additionally reduced TG and thrombus formation in both clopidogrel responders and nonresponders.

Copyright © FUJIMORI KOGYO CO.,LTD. All Rights Reserved.